Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Area of Science:

• Immunology
• Oncology
• Gene Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy represents a novel approach in cancer treatment.
• CARs engineered with CD19 specificity, CD137 (4-1BB), and CD3-zeta signaling domains were designed for enhanced T-cell function.

Observation:

• A patient with refractory chronic lymphocytic leukemia (CLL) received a low dose of autologous CAR T-cells.
• CAR T-cells demonstrated significant in vivo expansion, exceeding 1000-fold the initial engraftment level.
• Delayed onset of tumor lysis syndrome and lymphopenia were observed as adverse effects.

Findings:

• Complete remission was achieved in the CLL patient.
• Engineered CAR T-cells persisted at high levels for at least 6 months in blood and bone marrow.
• Sustained immune response targeting CD19-expressing cells, including leukemia and normal B cells, was detected.

Implications:

• This study highlights the potential efficacy of CD19-targeted CAR T-cell therapy for refractory CLL.
• Long-term persistence and specific anti-leukemic activity suggest durable responses.
• Management of toxicities like tumor lysis syndrome and lymphopenia is crucial for patient safety.